✦ LIBER ✦

Efficacy and side effects of intermittent recombinant interferon-α2a in chronic aggressive hepatitis C: With or without initial daily administration

✍ Scribed by HIDEKAZU ITOH; HIDENORI NAKATA; YUKIHIRO YOKOYA; SHOICHI NAKASHIMA; TETSUJI YAMANISHI; TAKESHI HARA; JUN KAWAI; HISAO MIYAMOTO; KATSUHIKO HIGASHI; SHINGO NISHIOKA

Book ID: 115170951
Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 487 KB
Volume: 11
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.1996.tb00320.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prolongation of daily administration of

Prolongation of daily administration of interferon(IFN) α-2a in patients with chronic hepatitis C (CHC): Efficacy and features predictive of response to IFN

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 170 KB

P-316 Interferon-α 2A therapy for chroni

P-316 Interferon-α 2A therapy for chronic hepatitis C-effect of its initial daily administration of longer duration according to HCV RNA level and genotypes

✍ Y Inagaki; N Tsukada; Y Yonei; K Miyamoto; O Suzuki; Y Kiryu; H Saito; H Ishii; 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 113 KB

A randomized trial of pegylated-interfer

A randomized trial of pegylated-interferon-α2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin

✍ A. CIANCIO; A. PICCIOTTO; C. GIORDANINO; A. SMEDILE; M. TABONE; A. MANCA; G. MAR 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB

Controlled and randomized trial about α2

Controlled and randomized trial about α2b-recombinant interferon in the treatment of chronic active hepatitis (CAH) HBS Ac+ with or without upper infection with delta viruses (DV)

✍ Buligescu, L.; Babes, V.; Popescu, A.; Voiculescu, M.; Snanache, S. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Efficacy, quality of life, safety, and t

Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN α-2a (PEGASYS®) or standard interferon Alfa-2b/ribavirin (REBETRON™) combination therapy

✍ Kenneth D. Rothstein; Robert P. Perrillo; Joanne Imperial; Imtiaz Alam; Melissa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 366 KB

A phase II randomized, double-blind, pla

A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB